Valuing Celegene’s CVR IB Prospect in IB-M&A Subscribe Share Share Copy Link Share on Facebook Share on X Share on LinkedIn Share on WhatsApp Share via Email Anyone ever look at the HBS case study? Should Tanaka buy more CVRs, hold, or sell her CVRs? Thanks! Region United States - Northeast All United States